DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
September 16, 2010
205 JEFFERSON STREET JEFFERSON CITY, MO 65101

Committee Members Present
Henry Petry, DO, Chairman
Joe Parks, MD (via teleconference)
Conrad Balcer, DO
Pat Bryant, PharmD

Committee Members Absent
Steve Calloway, RPh
Gene Forrester, RPh

Contractors Present
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, PharmD, MD, ACS
Sophie Backes, ACS
Tom Beetem, RPh, IFOX
Morgan Sperry, PharmD UMKC, DIC
David Preston, UMKC,DIC
Rick Pope, PharmD, First Health Services

MO HealthNet Staff Present
George L. Oestreich, PharmD, Dep. Division Dir
Rhonda Driver, RPh, Director Pharmacy
Tisha McGowan, Unit Supervisor
Andrew Haslag, Fiscal Manager
Jayne Zemmer, Program Manager
Beth McQuaide, Special Assistant
DJ Johnson, Program Development Specialist
Allison Lauf, RN
Mary Heet, RN
Jenna Twehus, RN

Ashley Nixon-Mongler, Student Intern

Others in Attendance*
Jim Graham, Centocor Ortho Biotech
Sarah Heldman, Student
Diane Racicot, Strativa
Sheri Henderson, Pfizer, Inc.
Phil King, Pfizer, Inc.
William Dozier, Gilead
Marcus Braddly, Achelion
Chad Stewart, Boehringer Ingelheim
David Rhein, Lilly
Lisa Steelman, Novartis
Brian Hutchinson, Acorda
Tracy Gaseri, UCB
C. Griffith, UCB
Glenda Lewis, Gilead
Lisa Gaughan, Actelion
John Harris Abbott
Terry Rehmus, Centocor Ortho Biotech
Randy Beckner, GlaxoSmithKline
Eric Gardner, Pfizer, Inc.
Rick Learner, Pfizer, Inc.
Rick Vissing, Pfizer, Inc.
Sam Smothers, MedImmune
Jeff Knappen, Allergan
Maurice Jackson, Boehringer Ingelheim

Paul Setlak, Abbott
Patty Minear, Eli Lily
Michael Jones, GlaxoSmithKline
Kim Lanergan, Astra Zeneca
Ted Berden, Alcon
Deborah Mance, Biogen
Cindi Keele, NAMI Missouri
Susan Zalenski, Johnson and Johnson
Don Larson, Forest
Debbie King, Amgen
Carl A. Curtis, Astra Zeneca
Deena Kegler-Ebo, Acorda
Lon Lowrey
Jim McNamara ViiV Healthcare
Grant Cale, BMS
Jeff Himmelberg, GlaxoSmithKline
Brad Clay, Amgen
Scott Edelhauser, Alcon
Ron Schnare, Shire
Jared Lurk, Novartis
James Osborne, GlaxoSmithKline

*Many names on the sign-in sheet were illegible/Sign-in sheet on file for review

Welcome, Introductions and Opening Remarks	The meeting was called to order by Chairman, Henry Petry, DO at 10:00 a.m. Copies of correspondence received by the Division regarding products under review this quarter was shared with the Committee. Each letter was responded to by the MO HealthNet Division (MHD). Ashley Nixon-Mongler a student intern with UMKC-Columbia was introduced.
Minutes Approval	Minutes from the June 2010 meeting were approved as submitted.
Pharmacy Program Budget Update	Due to the long agenda and in the interest of time the usual PowerPoint presentation was waived. George L. Oestreich, PharmD, MPA, Deputy Division Director provided a brief overview of the budget, The Unit has been working on the Health Information Exchange (HIE) initiative, the implementation of a radiology benefit management tool, inpatient certification. Dr. Oestreich alluded to a new tool under development for internal and external case management. Dr. Oestreich responded to a question from the audience regarding rumors that the state was considering rolling pharmacy back to managed care from Fee-for-Service. There is no plan to return the pharmacy benefit to managed care.
DUR Report	Tisha McGowan, Unit Supervisor reported the DUR Board met in July; reviewed and ratified the Drug PA Committee's June meeting recommendations.
Old Business	
Clinical Edits **Smoking Cessation in Pregnant Women**	●Discussion-Rhonda Driver, RPh, Director Pharmacy Program reviewed the edit proposal document noting all medications are available however must be used in conjunction with appropriate behavioral interventions if more than 30 days use is required as recommended in all guidelines. Discussion ensued surrounding these drugs and their Class C rating for use in pregnancy. Ms.

	Driver explained use will be at the discretion of the prescriber. ●Public Hearing-No comments were entered. ●Decision-Following this discussion the Committee vote to accept the edit as presented. (See Roll Call Vote)
Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits* was included in the members' meeting packet and as a handout to all attendees. The schedule had been updated with all edits approved at the last quarter's meeting. This included the implementation following the annual review for one third of the PDL approved in June and July. She noted that the Atypical Antipsychotic edit is scheduled for implementation in mid October. The schedule may be found on the MO HealthNet Division's (MHD) Web-site at http://dss.missouri.gov/mhd/cs/pharmacy/imsched.pdf.
New Business	
New Drug Review	● Discussion- Drug monographs for new products identified in April, May and June by first Data Bank and reviewed during this quarter were available at http://www.heritage-info.com/mohealthnet. A listing of products detailing MHD's recommendations for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all in attendance. Ms. Driver reviewed the recommendations and responded to Committee questions. ● Public Hearing-Kim Lonergan, RN, MSN speaking for Astra Zeneca in support of Vimovo®. Ms. Lonergan focused on the unique aspects of the product, including the delayed release of naproxen. She summarized two studies of the product also focusing on the unique aspects of each. She stated the product was developed for a very targeted patient population, those needing long term NSAID therapy and not intended or acute use. She discussed patient tolerance and product safety. David Rhein, PharmD, Eli Lilly addressed the Committee in support of Livalo®. Dr. discussed product indications, dose range, contra-indications. Effacacy evaluation trials were summarized. Adverse reactions to the product and safety data were discussed. Drug metabolization was discussed and Dr. Rhein stated this reduces the potential for drug-drug interaction for patients on multiple medications.

	● Decision-Following this discussion the Committee voted to accept the new drug recommendations as presented. (See Roll Call Vote)
PDL Edits	Copies of proposed criteria for all classes under review were provided in the member's meeting packets as well as to all attending. An annual review was conducted for the drug classes with Preferred Drug List (PDL) contracts expiring in January 2011.
Ace Inhibitors	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class from the previous year's status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ace Inhibitor/Diuretic Combination	● Discussion- Ms. Driver reviewed the criteria document noting no change to the current edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ace Inhibitor/Calcium Channel Blocker Combinations	● Discussion- Ms. Driver summarized this document noting no changes to the current edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. In the interested of time the Committee agreed to block votes for edits with no recommended or only new product additions to the previous year's edit, unless discussion warranted a separate vote. (See Block I Roll Call Vote)
Alpha-Glucosidase Inhibitors	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status had not changed. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Alzheimer's Agents	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status and approval

	criteria. No change to product coverage was being recommended with the exception the movement of Rivastigmine Caps to preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Angiotensin Receptor Blockers	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. A new product, Losartan, was added to the edit in non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Angiotensin Receptor Blocker/Diuretic Combinations	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. New product Losartan HCTZ was added to non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Antidiabetic Combination Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. A new product, ActosplusMet XR® was added to non preferred status. Ms. Driver reminded members that the additional criteria surrounding heart failure and TZD products will continue with this edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Biguanides	● Discussion Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class which is a generics first edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block I Roll Call Vote)
Bone Ossification Suppression Agents/Calcitonins	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Boniva® Tabs

	were moved from preferred status to non preferred and Prolia® Syringe, a new product and the first biologic to this class, was added to non preferred status. ● Public Hearing- Brad Clay, PharmD, Amgen shared information on the product Prolia®. He noted that the company is not seeking preferred status, however would ask the Committee to consider amending the approval criteria to allow trial and failure of one rather than two preferred agents to reach the product transparently. Dr. Clay shared slides discussing indications, administration, bone remodeling and the action of Prolia®. Two studies were summarized. Safety and adverse events were discussed. Questions were answered regarding mechanism of action. Extensive discussion ensued surrounding the definition of trial and fail in the editing process. ● Decision- Following review of the proposal and public comment the recommendation was approved as submitted. (See Roll Call Vote)
Direct Renin Inhibitor **Direct Renin Inhibitor/Combinations**	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting that all products were recommended for preferred status including a new addition to the class, Valturna®. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Electrolye Depleters	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting no changes to the products recommended for preferred and non-preferred status. ● Public Hearing-No comment was entered ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block II Roll Call Vote)
Herpes Antivirals	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block II Roll Call Vote)
DMARDS	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the addition of two new products, Actemra® and Stelara® to non preferred status. Clinical criteria including appropriate diagnosis and history of methotrexate trial

	remain in place. The trial and failure on preferred agents was also lowered from three preferred agents to two to reach a non preferred agent. ● Public Hearing-Curt Griffith, PharmD with UCB asked the Committee to consider Cimzia® for preferred status. Dr. Griffith asked for clarification on trial and failure and also for clarification surrounding the diagnosis of Chron's Disease. Ms. Driver summarized clinical criteria within the document. Dr, Griffith discussed the expansion of the class and ACR criteria. This lead to discussion of MHDplans for specialty management and edit development over the next five to seven years, Terry Rehmus, PharmD, Centocor Ortho Biotech provided information on the new product Sterla® a first in class biologic treatment for plague psoriasis. Product indications, administration and dosing were summarized. Dr. Rehmus provided data from product studies. Side effects were reviewed. The Committee was asked to consider creating a psoriasis specific category as the product is not a DMARD. ● Decision- Following review of the proposal, the public comment and discussion the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Leukotriene Modifiers	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status Zyflo CR ® was moved to non preferred status and new product Zyflo® was added to the edit in non preferred status. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Lipotropics-Niacin Preparations	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the movement of Simcor® from preferred to non preferred status. Clinical criteria for Simcor® remain in place. ● Public Hearing-No comments were entered. Abbott Pharmaceuticals noted there are two new dosage strengths of Simcor under review. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Low Sedating Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the

	products recommended for preferred and non-preferred status. No change was recommended. . ● Public Hearing-No public comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Low Sedating Antihistamines/Decongestant Combinations	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No changes were recommended. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Macrolides Adult/Pediatric	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. This is a generics first edit. No change was being recommended for this therapeutic class. . ● Public Hearing-no public comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Meglitinides	● Discussion-Ms. Driver reviewed the proposed criteria document. Prandin® was recommended as preferred and moved from the non preferred. Trial and failure on both preferred agents was recommended before reaching the non preferred agent. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block III Roll Call Vote)
Multiple Sclerosis Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting a new product addition to non preferred agents, Extavia®. A trial on two preferred agents to reach the non preferred agent was added to approval criteria. Ms. Driver clarified that the Division had no intentions of placing the product Amprya® in this class in response to a question from the audience. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block IV Roll Call Vote)

Narcotics: Long Acting	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status including the addition of a new product, Exalgo ER® to non preferred status. Clinical edit criteria remain in place. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block IV Roll Call Vote)
Intranasal Steroids	● Discussion-Ms. Driver reviewed the proposed criteria document. No changes were recommended. ● Public Hearing- No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block IV Roll Call Vote)
Ophthalmic Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Ms. Driver reviewed the proposed criteria document noting a new product addition to non preferred status, Azelastine Oph. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Ophthalmic Mast Cell Stabilizers	● Discussion-Ms. Driver reviewed the proposed criteria document noting no change to the existing criteria. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block IV Roll Call Vote)
Ophthalmic Qinolones	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status including the addition of a new product, Zymaxid®, to non preferred status. ● Public Hearing- No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block IV Roll Call Vote)
Ophthalmic Prostaglandin Agonists	● Discussion-Ms. Driver summarized the proposed criteria document noting that all products in the therapeutic class remain preferred following this review. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the

	recommendation as presented. (See Block IV Roll Call Vote)
Pulmonary Hypertension Agents(Oral/Inhaled/Injectable)	● Discussion-Ms. Driver reviewed the proposed criteria documents which included the movement of Adcirca® to preferred status for oral products. No changes were recommended for the inhaled/injectable edit. Ms. Driver pointed out the clinical criteria still in place for approval and also discussed Missouri's data that shows the state as on outlier compared to several other states in its utilization of this therapeutic class. Members suggested that MHD consider more stringent diagnostic criteria and wish to revisit this edit when additional data is available ● Public Hearing- Glenda Lewis, PharmD, Gilead reviewed a handout discussing the product Letaris®. Dr. Lewis focused on functional class indications, LFT profile, the products drug interaction profile, and guideline recommendations. She requested Letaris® be considered for preferred status. ● Decision- Following review of the proposal and public comment the Committee voted to accept the recommendations as presented. (See Roll Call Vote)
Otic Quinolones	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Quinolones-Systemic	● Discussion-Ms. Driver reviewed the proposed criteria document. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
2nd Generation Sulfonylureas	● Discussion-Ms. Driver reviewed the proposed criteria document. No change was being recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Serotonin Receptor Agonists	● Discussion-Ms. Driver reviewed the proposed criteria document noting the

(Triptans)	addition of a new product to the therapeutic class, Naratriptan. Naratriptan was recommended as a non preferred product. The maximum daily dosing edit for these products remains in the edit. ● Public Hearing- No public comment was entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented with modification to the compliance model for Relpax® to use claim count data. (See Block V Roll Call Vote)
Thiazolidinediones	● Discussion-Ms. Driver reviewed the proposed criteria document. No change was being recommended for this therapeutic class. Heart failure risk clinical criteria will remain in place. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Topical Agents of Psoriasis	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended for this therapeutic class. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Topical Retinoids	● Discussion-Ms. Driver reviewed the proposed criteria document. Adapalene a new entry to the therapeutic class was added to the edit in non preferred status. Ms. Driver pointed out clinical criteria remains in place for approval. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Ulcerative Colitis Agents Oral and Rectal	● Discussion-Ms. Driver reviewed the proposed criteria documents. Noting the shifting of Pentasa® to preferred status in the oral category. Ms Driver pointed out clinical criteria remains in place for approval. A reduction in the number of preferred agent trials to one to reach non preferred agents was recommended for the rectal agents. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendations as presented. (See Block V Roll Call Vote)

Vaginal Antibiotics	● Discussion-Ms. Driver reviewed the proposed criteria document. No change to this therapeutic class was recommended. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Intranasal Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Changes included the movement of Astelin® from preferred status to non preferred and the addition of new product, Azelastine Nasal to the non preferred side of the edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See See Block V Roll Call Vote)
Crypytin Associated Periodic Syndrome Agents	● Discussion-Ms. Driver reviewed the proposed criteria document noting no recommended changes to the existing edit. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Self-injectable Epinephrine Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. The addition of two new products in the therapeutic class (Adrenaclick® and Epinephrine® to non preferred status was noted. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Tramdaol Like Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. No change to the existing criteria or product status was made. ● Public Hearing-No comments were entered. ● Decision- Following review of the proposal the Committee voted to accept the recommendation as presented. (See Block V Roll Call Vote)
Fibromyalgia Agents	● Discussion-Ms. Driver reviewed the proposed criteria document. No changes to the current edit were recommended. ● Public Hearing-Rick Vissing, PharmD, Pfizer provided a brief synopsis of the product Lyrica®. He discussed the unique mechanism of action for the product. He discussed trials which lead to FDA approval of the product. He continued

	his presentation with the management of the disease state and use of multimodal therapy. He discussed the need for different mechanism of action for effective treatment stating both preferred products have the same mechanism of action. Dr. Vissing responded to questions regarding monotherapy versus combination therapy first line and the guidelines to support. He stated there were no published guidelines however; clinical practice consensus supports multimodal therapy. Discussion ensued surrounding a multidisciplinary approach for the treatment of this condition. ● Decision- Following review of the proposal and public comment the Committee voted to accept the recommendation as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories for review and inclusion in the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's Web page at http://www.dss.mo.gov.mhd. The posting will also be updated with the MHD recommendations prior to the December Drug Prior Authorization Committee meeting.
Program Utilization Information	A listing of the top 25 drugs for all quarters of 2009 and the 1st and 2nd quarter 2010 was provided for the Committee's Information. Copies were available to all attendees. This information was shared by product and paid claims rankings.
Clinical Edit Summary Report	An overview of clinical edit and prior authorization transactions was provided for the month of August 2010 was included in the meeting packet.
Call Center Statistics	A handout detailing pharmacy help desk cal center activity was provided for all attending. Statistics for August 2010 were included. A report detailing CyberAccess™ activity from inception to present was also included.
Adjourn	The next meeting of the Committee is scheduled for December 16, 2010. A handout featuring meeting dates in 2011 was provided to all attendees. The Drug PA Committee went into executive session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See Roll Call Vote)

Roll Call Votes
September 16, 2010

Member	New Drug Review	Smoking Cessation	Ace Inhibitors	Ace Diuretic Combinations	Block Vote I	Bone Ossification	Direct Renin	Block Vote II	DMARDS	Block Vote III
Petry	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Forrester	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Calloway	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Bryant	**Second**	Yeah	**Second**	**Motion**	**Second**	**Second**	Yeah	**Second**	**Second**	**Second**
Balcer	**Motion**	**Second**	**Motion**	**Second**	**Motion**	**Motion**	**Motion**	**Motion**	**Motion**	**Motion**
Parks	Yeah	**Motion**	Yeah	Yeah	Yeah	Yeah	**Second**	Yeah	Yeah	Yeah

Member	Block Vote IV	Pulmonary Hyperten Agents	Block Vote V	Fibromyalgia	Closed Session	Adjourn
Petry	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Forrester	Absent	Absent	Absent	Absent	Absent	Absent
Calloway	Absent	Absent	Absent	Absent	Absent	Absent
Bryant	Yeah	**Second**	**Second**	**Second**	**Motion**	**Second**
Balcer	**Second**	**Motion**	**Motion**	**Motion**	**Second**	**Motion**
Parks	**Motion**	Yeah	Yeah	Yeah	Absent	Absent

Executive Session
September 16, 2010

Committee Members Present
Henry Petry, DO, Chairman
Joe Parks, MD
Conrad Balcer, DO
Pat Bryant, PharmD
Joe Parks, MD

Committee Members Absent
Steve Calloway, RPh
Gene Forrester, RPh

Contractors Present
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, PharmD, MD, ACS
Sophie Backes, ACS
Tom Beetem, RPh, IFOX
Morgan Sperry, UMKC, DIC

MO HealthNet Staff Present

George L. Oestreich, PharmD, Dep. Division Dir
Rhonda Driver, RPh, Director Pharmacy
H. Diana Jones, Director Clinical Services
Lisa Clements, PhD, Clinical Director Psychology
Beth McQuaide, Special Assistant
Andrew Haslag, Fiscal Manager
Allison Lauf, RN
Mary Heet, RN
Jenna Twehus, RN
DJ Johnson, Program Development Specialist
Jackie Hickman, Unit Supervisor

Minutes Review	Minutes of the June 2010 Executive Session were approved as submitted.
Case Reviews	No cases were presented for review due to the large ageda.
Adjourn	The meeting adjourned. (See Roll Call Votes)